Radioimmunotherapy in Non-Hodgkin’s Lymphoma: Retrospective Adverse Event Profiling of Zevalin and Bexxar

The development of monoclonal antibodies has dramatically changed the outcome of patients with non-Hodgkin’s lymphoma (NHL), the most common hematological malignancy. However, despite the satisfying results of monoclonal antibody treatment, only few NHL patients are permanently cured with sing...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Christos Sachpekidis, David B. Jackson, Theodoros G. Soldatos
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	MDPI AG 2019-09-01
Serie:	Pharmaceuticals
Soggetti:	non-Hodgkin’s lymphoma radioimmunotherapy <sup>90</sup>Y-ibritumomab tiuxetan (Zevalin), <sup>131</sup>I-tositumomab (Bexxar), FDA’s Adverse Event Reporting System (FAERS), VigiBase
Accesso online:	https://www.mdpi.com/1424-8247/12/4/141
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!